HOME >> MEDICINE >> NEWS
FDA approves Dey, L.P.'s Perforomist inhalation solution for maintenance treatment of COPD

Napa, CA (May 11, 2007) Dey, L.P. announced today that the Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Perforomist (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Formoterol is a rapid and long-lasting beta2 agonist that has been previously approved in the U.S. as a dry powder formulation, and the molecule has twenty years of worldwide use. Perforomist Inhalation Solution is the first and only FDA-approved nebulized formoterol fumarate. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

"The first nebulized formoterol fumarate, Perforomist Inhalation Solution offers a new treatment option to COPD patients," said Nicholas J. Gross, MD, PhD, Principal Investigator of the Phase III pivotal clinical trial and an expert on lung diseases, particularly COPD. "By nebulizing with Perforomist Inhalation Solution twice a day once in the morning and once in the evening many COPD patients can achieve better control of their disease symptoms. The convenience of such simple dosing combined with a drug delivery option favored by many patients may provide improved symptom control and a better quality of life for the millions of Americans who live with COPD."

Mel Engle, President and CEO at DEY, noted, "As the US leader in nebulized respiratory products, we are thrilled to bring Perforomist Inhalation Solution, a new patented treatment option for COPD patients, to the market. Nebulization is a time tested and reliable drug delivery option. DEY has a long history of developing and marketing innovative respiratory therapeutics. The approval of Perforomist Inhalation Solution fits perfectly with our overall strategy for respiratory medications."

Gene L. Colice, MD, Department
'"/>

Contact: Harriet Ullman
harriet.ullman@fkhealth.com
617-761-6776
Feinstein Kean Healthcare
11-May-2007


Page: 1 2

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
3. VCR -- FDA approves home discharge for US patients
4. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
5. FDA approves Vectibix to treat patients with metastatic colorectal cancer
6. 5,000 rare diseases need drugs, but Europe only approves a handful each year
7. FDA approves room temperature storage of ZLB Behrings Helixate FS
8. FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference

Post Your Comments:
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... 15, 2014 Veretekk.com, Inc. announced today ... Avenue. JM Ocean Avenue has secured exclusive benefit ... automated marketing system. JM Ocean Avenue is a ... of Ocean Avenue and JM International, with partial ownership ... per year company. , “After nearly 2 decades of ...
(Date:12/15/2014)... 15, 2014 OutMarket , a ... “ Social Media Cheat Sheets ,” a guide that ... drives results on the top ten social media networks. ... helps drive awareness, engagement, and customer service. It can ... make an impact on new networks and weather constantly ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in ... is contributing to the growth in the global audiological market. ... hearing loss and balance disorders are known as audiological devices. ... and amplifier. The global market is expected to grow at ... from 2014 to 2019. Some of the factors which are ...
(Date:12/15/2014)... 2014 At the leading, long-established event ... and Focus Autism will welcome scientists ... on the effects of toxins to children’s health, as ... , Luminaries such as Dr. Lucija Tomljenovic and ... esteemed, credentialed colleagues of the United States to present ...
Breaking Medicine News(10 mins):Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, Inc. ... has been added to the NASDAQ Biotechnology Index ... will become effective upon market open on December ... is designed to track the performance of a ... either biotechnology or pharmaceutical according to the Industry ...
(Date:12/15/2014)... As medical device manufacturers join pharmaceutical companies ... standard, content teams have a greater role to play ... the standard. Starting January 2015, Data Conversion Laboratory (DCL) ... benefits and the critical aspects of implementing SPL. ... Howard Shatz , DCL,s SPL expert, and will ...
(Date:12/15/2014)... BOSTON , December 15, 2014 ... discovery and development company, is pleased to announce the ... United States relating to its GPCR-focused drug ... US significantly strengthens the global patent estate covering Heptares, ... The suite of patents recently granted by the ...
Breaking Medicine Technology:Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
Cached News: